Subsidies & Funding

We empower medical innovation

Project Management

We manage research & innovation projects

Business Strategy

We support successful commercialisation


New IMI-Calls Addresses Obesity and Environmental Risks Caused by Human Medicinal Products

February 20 2019

The Innovative Medicines Initiative (IMI) focuses on the development and accessibility of new-generation medicines. The initiative is focused on improving health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need.

Three topics

IMI will make approx. 77 million euros available (half of which will be in-cash) for the next deadline for three urgent topics:

  • Optimization of future obesity treatment
  • Set-up of a 'druggable' genes library accessible to researchers
  • Prediction and identification of environmental risks posed by new medicinal products.

Obesity treatment

This topic relates to a development of a database on basis of which a better picture of obesity (subcategories) can be obtained. It should lead to a better and, above all, common understanding of obesity, helping the disorder to be generally recognized as a disease. Furthermore, this should allow to carry out more effective communication with the emphasis on the importance of weight loss and weight maintenance.

Setting up a gene library accessible to researchers

One of the frustrations in the medical world is that there is still insufficient knowledge of the relationship between genes and disorders, which prevents new medicines from being developed as quickly. Big data will contribute to minimising this problem, however, it is not that far yet.

The IMI wants to encourage public-private partnerships to develop a gene library containing at least 1,000 genes that can be switched on or off with small molecules (thus, not large biological molecules). This is especially important for research where function of a particular gene must be determined quickly. The results will be completely public leading, therefore, to a much more efficient and faster exchange of knowledge in this area.

Intelligent prediction and identification of environmental risks posed by human medicinal products

Currently, in the development of new medicines, a comprehensive analysis of the impact on the environment only takes place if there is a reason to do so based on a rough risk analysis. Often this risk assessment analysis takes place late in the development process, or not at all. As a result of stricter regulations, but also to maximally reduce environmental risks, IMI wants to investigate the possibilities of identifying risks earlier in the development process.

Practical information about this IMI subsidy round

The subsidy provider offers loads of additional information to parties that want to respond to one of these calls. For each component of this subsidy round (formally IMI2 – Call 17), partnerships of organizations can submit an application, in which SMEs with expertise in this field are encouraged to participate. The first-phase application (a proposal of maximum 30 pages) in which you indicate why your consortium and your approach is the best, must be submitted no later than April 25th. The second, more extensive proposal (70 pages), must be submitted no later than 7 November 2019 (only one preproposal is invited for the second round for each of the above topics).

The Life Sciences & Health experts at ttopstart have extensive expertise in this field and have a substantial network for the formation of partnerships. In case you are interested in the call or would like to get more information, please, contact our experts by filling out the form below:

Share this